NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Insights - Inspire Medical Systems, Inc. is facing a class action lawsuit for allegedly misleading investors regarding the launch of its Inspire V Device, which was anticipated to significantly increase revenue [1][5] - The lawsuit highlights operational failures, including insufficient training for treatment centers and IT system issues, leading to a more than 80% reduction in the company's 2025 earnings guidance [2][5] - Following the earnings guidance cut, the stock price plummeted over 32%, resulting in a loss of $1.2 billion in market capitalization [2] Financial Performance - The company's stock has shown considerable volatility, with a 52-week high of $216.01 and a low of $70.77 [4] - As of the latest trading, the stock is priced at $125.22, despite a recent decrease of 1.66%, equating to a $2.11 drop [3][5] - Wolfe Research upgraded Inspire's stock to "Outperform" on November 25, 2025, indicating potential for recovery [3][5] Market Position - Inspire Medical Systems has a current market capitalization of approximately $3.71 billion, with a trading volume of 508,655 shares [4] - Shareholders interested in the class action lawsuit must submit their papers by January 5, 2026, with Robbins LLP managing the case on a contingency fee basis [4]

INSP CLASS REMINDER: Inspire Medical Systems, Inc. Investors with Losses are Reminded to Contact BFA Law before the Imminent January 5 Securities Class Action DeadlineNovember 28, 2025 8:18 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 28, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the lawsuit is from August 6, 2024, to August 4, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and investors wishing to serve as lead plaintiffs must act by January 5, 2026 [4][8]. Group 2: Allegations Against Inspire Medical - The lawsuit alleges that Inspire Medical misrepresented and failed to disclose critical information regarding the Inspire V sleep apnea device, including actual market demand and necessary steps for its launch [6]. - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the Inspire V device, resulting in investor damages when the truth was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for settlements in 2017 [5]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has consistently ranked in the top 4 for securities class action settlements since 2013 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026 [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by January 5, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and readiness for launch, leading to investor losses when the truth was revealed [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors that it had taken necessary steps for the launch of Inspire V, claiming high demand would support the rollout [5]. - Contrary to these assurances, the company allegedly failed to prepare clinicians and payors adequately, leading to significant delays and weak demand due to excess inventory of older devices [6]. - On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price fell by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements regarding the demand and launch of its implantable medical device for obstructive sleep apnea [4][5]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Inspire securities between August 6, 2024, and August 4, 2025, alleging that the company made false statements about the demand for its product and the success of its launch [4]. - Allegations include that Inspire failed to disclose poor demand for its device, as providers had surplus inventory and were hesitant to adopt the new treatment [4]. - The company admitted on August 4, 2025, that the launch of Inspire V was delayed due to incomplete training and onboarding at treatment centers, which affected billing for procedures [5]. Group 2: Financial Impact - Following the announcement of the launch issues and reduced earnings guidance by over 80%, Inspire's share price dropped by $42.04, or approximately 32.35%, from $129.95 to $87.91 on August 5, 2025 [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the launch and performance of its Inspire V Device, which has reportedly underperformed in the market [1][3][4]. Company Overview - Inspire Medical Systems, Inc. is a medical technology company that develops and manufactures an implantable device for treating obstructive sleep apnea, known as the Inspire V Device [1][3]. Allegations and Issues - The lawsuit claims that the company misrepresented the potential of the Inspire V Device, which was marketed as groundbreaking but faced poor demand and significant inventory issues among providers [3][4]. - Key failures cited include inadequate training for treatment centers, lack of essential IT systems, and unpreparedness for insurance claims processing, which were critical for a successful product launch [4]. Financial Impact - On August 4, 2025, the company announced a significant reduction in its 2025 earnings guidance by over 80%, dropping from a range of $2.20 to $2.30 per share to just $0.40 to $0.50 per share [5]. - Following this announcement, the stock price plummeted by $42.04 per share, a decline of more than 32%, resulting in a loss of $1.2 billion in market capitalization in a single day [5]. - From a high of $216.71 per share on September 23, 2024, the stock has decreased by nearly 60%, erasing billions from the company's market capitalization [5].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding the launch of its Inspire V device for obstructive sleep apnea, which resulted in a significant decline in stock price [1][5]. Company Overview - Inspire Medical Systems, Inc. specializes in implantable neurostimulation technology aimed at improving respiration during sleep [3]. Legal Proceedings - The lawsuit, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., targets the company and its executives, representing investors who acquired stock between August 6, 2024, and August 4, 2025 [2][6]. - The lead plaintiff deadline for the lawsuit is set for January 5, 2026 [2]. Allegations - The complaint alleges that the company misrepresented the transition to the Inspire V device as seamless, while in reality, it faced significant operational challenges [3][6]. - Key allegations include poor market demand, incomplete readiness for the launch, and undisclosed logistical issues that hindered the rollout of the Inspire V device [8]. Market Reaction - On August 4, 2025, Inspire Medical publicly acknowledged that the launch of the Inspire V device was facing an "elongated timeframe," leading to a drastic reduction in 2025 earnings guidance by over 80% [4][5]. - Following this announcement, the company's stock price plummeted by over 32% on heavy trading volume [5]. Investigation Focus - Hagens Berman is investigating potential misstatements or omissions related to the Inspire V device launch and its financial implications [7]. - The investigation is particularly focused on whether management was aware of critical operational flaws, such as billing code delays and training deficiencies, prior to the public disclosure [9].

Core Insights - Inspire Medical Systems, Inc. (NYSE:INSP) has recently experienced significant stock performance, reaching a three-month high due to bullish coverage and a price target upgrade from Wolfe Research [1][2] - Wolfe Research upgraded Inspire Medical's rating from "peer perform" to "outperform" with a new price target of $180, indicating a 38% upside potential from its latest closing price [2] - The revision in price target is attributed to updates in Medicare's outpatient payment structure, which will increase payments for Inspire Medical procedures from $30,000 to $45,000 [3] Financial Performance - Inspire Medical reported a net income of $9.9 million for Q3, reflecting a 46% decline from $18.5 million in the same period last year [4] - Despite the decline in net income, revenues increased by 10.5% year-on-year to $224.5 million, driven by a 9% growth in US operations, amounting to $214.4 million [4] - For the full year 2025, the company maintains its revenue guidance of $900 million to $910 million, implying a year-on-year growth of 12 to 13% [5]